Exa-cel shows complete success in early pediatric trials for sickle cell disease and beta-thalassemia
Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger than 12.